Reshma Kewalramani

“It is very surprising for me to see so many of you at an ASN. And it is a real pleasure to see all of you here for the Vertex event. Believe it or not, when I was an actual practicing nephrologist and would come to ASN as a doctor, there were no real analyst meetings.”

“Vertex's second quarter performance was excellent, with strong momentum in the commercial portfolio, rapid progress across our R&D pipeline, and the announcement of the definitive agreement to acquire Cronetics Pharmaceuticals, which brings rare endocrine diseases as a fifth pillar to Vertex.”

“We are excited to announce that we've entered into a definitive agreement to acquire Crenetics Pharmaceuticals for $85 per share in cash in a transaction with a total equity value of about $10 billion or $8.8 billion net of estimated cash acquired.”

“First of all, it's very nice to be here with you, Salveen. I know we're the last fireside chat, so it's good to see those of you in the room. I've described 2026 and for the next 6, 12, 18 months as a year or period of time for Vertex.”

“Vertex is off to a terrific start in 2026, which we see as a year defined by execution. Q1 revenue growth was strong across the portfolio as we reached more patients with more products and delivered total product revenue of $2.99 billion, reflecting 8% growth year-on-year.”